Previous 10 | Next 10 |
Oxidative stress contributes to the formation of misfolded amyloid and tau proteins and to neuroinflammation all of which can further increase oxidative stress. Drugs that target pro-inflammatory cytokines such as INmune Bio's XPro1595 and Montelukast are likely too specific and too l...
Boca Raton, FL, April 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that management will participate at the B. Riley Neuro &am...
Clinical-stage immunology company INmune Bio (NASDAQ:INMB) on Wednesday announced the dosing of the first patient enrolled in its phase 2 trial using its tumor necrosis factor inhibitor XPro1595 to treat neuroinflammation caused due to Alzheimer’s disease. The phase 2 multicenter,...
Boca Raton, Florida, April 13, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune ...
Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab and tyrosine kinase inhibitors, and promotes an immunologically active tumor micro-environment Boca Raton, Flo...
INKmune therapy, NK cell therapy, was shown to activate NK cells that killed off >70% of NK resistant tumor cells in an in vitro assay in an MDS patient. INKmune approach will be used to activate dormant NK cells and allow them to kill off cancer cells; additional indications inclu...
INKmune™, unlike IL15 and other NK-activating cytokines, upregulates all mitochondrial survival proteins and more than 40 nutrient receptors on the NK cell to increase survival Boca Raton, Florida, April 04, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB)...
Boca Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immun...
Boca Raton, Florida, March 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight...
Gainers: JX Luxventure Limited (LLL) +43%. Alpha Tau Medical (DRTS) +37%. Takung Art (TKAT) +31%. Emclaire Financial (EMCF) +32%. BiondVax (BVXV) +30%. Mercurity Fintech Holding (MFH) +26%. INmune Bio (INMB) +19%. Gracell (GRCL) +21%. Aptevo (APVO) +21%. Lilium (LILM) +20%. LiqTech Internatio...
News, Short Squeeze, Breakout and More Instantly...
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...
2024-06-12 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual r...